Omegaven (fatty acids combo. no.6/fish oil/glycerin)
Lipids Intravenous Emulsion
Last reviewed · Source: First Databank (FDB) drug data
Overview
Generic name: fatty acids combo. no.6/fish oil/glycerin
Drug class: Lipids
Therapeutic class: Electrolyte Balance-Nutritional Products
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Omegaven
Indications
The following indications are listed for Omegaven:
- Tpn-Associated Cholestasis
Also known as: Biliary Stasis From Total Parenteral Nutrition, Biliary Stasis From Tpn.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Vitamin E (Alpha Tocopherol) >=800 Unit/Slt Anticoag (Vit K)
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Vitamin E may decrease vitamin K-dependent clotting factors, resulting in additive effects with vitamin K antagonists.(1)
CLINICAL EFFECTS: Dose of vitamin E of 800 units/day or more may increase the pharmacologic effects of vitamin K antagonists.(1-7)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Patients receiving vitamin E supplements of 800 units/day or more may require lower dosages of vitamin K antagonists. In patients maintained on warfarin who initiate vitamin E supplements in dosages of 800 units/day or more, measured INR one to two weeks after initiation of vitamin E and also every two to four weeks during the first two months.(2)
DISCUSSION: Vitamin E doses up to 400 units/day is believed not to affect the prothrombin time in patients concomitantly receiving warfarin.(2) Vitamin E doses of 800 International Units/day and more have been reported to increase the hypoprothrombinemic effect of warfarin. However, in a double blind clinical trial, with only 13 subjects completing the study, patients who had received chronic warfarin therapy with the addition of vitamin E dose as high as 1,200 IU/day for 1 month saw negligible change in the INR or prothrombin time.(3) Selumetinib capsules contain a significant amount of vitamin E. Each 10 mg capsule contains 32 mg (48 units) and each 25 mg capsule contains (54 units) of vitamin E. The daily dose of selumetinib may contain up to 256 mg (384 units) of vitamin E. Vitamin E supplementation is not recommended if it will result in a daily vitamin E intake exceeding recommended or safe amounts.(4) Agenerase brand of amprenavir capsules and oral solution contain a significant amount of vitamin E. Each 150 mg capsule contains 109 International Units vitamin E, with a total of 1,744 International Units of vitamin E in the recommended daily adult dose. Each mL of oral solution contains 46 International Units of vitamin E.(5) One or more of the drug pairs linked to this monograph have been included in a list of interactions that could be considered for classification as "non-interruptive" in EHR systems. This DDI subset was vetted by an expert panel commissioned by the U.S. Office of the National Coordinator (ONC) for Health Information Technology.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| TPn-associated cholestasis | ||
| K76.83 | ICD10CM | Intestinal failure-associated liver disease |
| K76.89 | ICD10CM | Other specified diseases of liver |
| K83.1 | ICD10CM | Obstruction of bile duct |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.